ESR1 and breast carcinoma: Neoadjuvant endocrine therapy (NET) is an important alternative to NAC for ER-positive, HER2-negative breast cancer, and previous trials established that NET with aromatase inhibitors (AIs) improved the response rates for postmenopausal women compared with tamoxifen [5, 6].